Management of Decompensated HCV Cirrhotic Patients

• Status: Completed
• Trial end date: 2018-06-24
• Target enrollment: 0
• Participant gender: All

Summary

-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation. The impact of DAAs therapy on mortality in decompensated cirrhosis was not investigated.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zagazig University
• Treatments: Antiviral Agents; Furosemide; Ribavirin; Silymarin; Sofosbuvir; Spironolactone; Vitamin K; Vitamin K 1

Criteria

Inclusion Criteria:

• chronic active HCV proved by the positivity of HCV RNA, elevated transaminases.

• CTP score was >9, MELD score was <29

• Decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to treat ascites

Exclusion Criteria:

• exposure to previous antiviral therapy

• hepatocellular carcinoma

• other causes of liver diseases or mixed causes (excessive alcohol consumption, autoimmune liver disease)

• previous liver transplantation.